mgmt p pyrosequencing Search Results


pyrosequencing-based mgmtp methylation score  (Pyrosequencing Inc)
90
Pyrosequencing Inc pyrosequencing-based mgmtp methylation score
Association between progression-free survival (PFS) and the <t>MGMTp</t> <t>methylation</t> score. The association of the MGMTp methylation score, based on the MGMT-STP27 procedure, with progression-free survival (PFS; interval from diagnosis) was evaluated by the hazard ratio (confidence interval at 95%) from the cox regression model. The forest plots in A and B correspond to the PFS reported for patients treated in EORTC-22033 with temozolomide (TMZ) or radiotherapy (RT), respectively. , The MGMT-STP27 score was significant in the TMZ treated patients, but not in the patients with RT. The forest plots in C and D visualize the outcome of the Montpellier patients treated with TMZ, with time to progression defined by the next treatment-free survival (NxtTrtFS), and PFS defined by RANO, respectively. The MGMT-STP27 score was significant in the Montpellier cohort when using NxtTrtFS as outcome measure, a trend was observed when using RANO criteria for PFS. * P <.05; ** P <.01.
Pyrosequencing Based Mgmtp Methylation Score, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pyrosequencing-based mgmtp methylation score/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
pyrosequencing-based mgmtp methylation score - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Association between progression-free survival (PFS) and the MGMTp methylation score. The association of the MGMTp methylation score, based on the MGMT-STP27 procedure, with progression-free survival (PFS; interval from diagnosis) was evaluated by the hazard ratio (confidence interval at 95%) from the cox regression model. The forest plots in A and B correspond to the PFS reported for patients treated in EORTC-22033 with temozolomide (TMZ) or radiotherapy (RT), respectively. , The MGMT-STP27 score was significant in the TMZ treated patients, but not in the patients with RT. The forest plots in C and D visualize the outcome of the Montpellier patients treated with TMZ, with time to progression defined by the next treatment-free survival (NxtTrtFS), and PFS defined by RANO, respectively. The MGMT-STP27 score was significant in the Montpellier cohort when using NxtTrtFS as outcome measure, a trend was observed when using RANO criteria for PFS. * P <.05; ** P <.01.

Journal: Neuro-Oncology Advances

Article Title: Clinical value of the MGMT promoter methylation score in IDHmt low-grade glioma for predicting benefit from temozolomide treatment

doi: 10.1093/noajnl/vdae224

Figure Lengend Snippet: Association between progression-free survival (PFS) and the MGMTp methylation score. The association of the MGMTp methylation score, based on the MGMT-STP27 procedure, with progression-free survival (PFS; interval from diagnosis) was evaluated by the hazard ratio (confidence interval at 95%) from the cox regression model. The forest plots in A and B correspond to the PFS reported for patients treated in EORTC-22033 with temozolomide (TMZ) or radiotherapy (RT), respectively. , The MGMT-STP27 score was significant in the TMZ treated patients, but not in the patients with RT. The forest plots in C and D visualize the outcome of the Montpellier patients treated with TMZ, with time to progression defined by the next treatment-free survival (NxtTrtFS), and PFS defined by RANO, respectively. The MGMT-STP27 score was significant in the Montpellier cohort when using NxtTrtFS as outcome measure, a trend was observed when using RANO criteria for PFS. * P <.05; ** P <.01.

Article Snippet: The association between the MGMT-STP27 score and NxtTrtFS was confirmed using a pyrosequencing-based MGMTp methylation score (MGMT-PYROscore) obtained for the same samples ( P = .002, ).

Techniques: Methylation, Biomarker Discovery